Document is current
Any future updates will be listed below
-
Authors
Yoshiji, Satoshi https://orcid.org/0000-0001-8863-2413
Butler-Laporte, Guillaume https://orcid.org/0000-0001-5388-0396
Lu, Tianyuan https://orcid.org/0000-0002-5664-5698
Willett, Julian Daniel Sunday
Su, Chen-Yang https://orcid.org/0000-0001-6071-4660
Nakanishi, Tomoko https://orcid.org/0000-0001-9510-5646
Morrison, David R. https://orcid.org/0000-0001-8380-3615
Chen, Yiheng
Liang, Kevin
Hultström, Michael https://orcid.org/0000-0003-4675-1099
Ilboudo, Yann
Afrasiabi, Zaman https://orcid.org/0000-0003-4395-5168
Lan, Shanshan
Duggan, Naomi
DeLuca, Chantal
Vaezi, Mitra
Tselios, Chris
Xue, Xiaoqing
Bouab, Meriem
Shi, Fangyi
Laurent, Laetitia
Münter, Hans Markus https://orcid.org/0000-0002-3165-2840
Afilalo, Marc
Afilalo, Jonathan
Mooser, Vincent https://orcid.org/0000-0002-8632-0448
Timpson, Nicholas J. https://orcid.org/0000-0002-7141-9189
Zeberg, Hugo
Zhou, Sirui
Forgetta, Vincenzo
Farjoun, Yossi
Richards, J. Brent https://orcid.org/0000-0002-3746-9086
- License Information
-
More Information
Article History
Received: 17 June 2022
Accepted: 10 January 2023
First Online: 20 February 2023
Competing interests
: J.B.R. has served as an advisor to GlaxoSmithKline and Deerfield Capital. The institution of J.B.R. has received investigator-initiated grant funding from Eli Lilly, GlaxoSmithKline and Biogen for projects unrelated to this research. J.B.R. is the CEO of 5 Prime Sciences (), which provides research services for biotech, pharma and venture capital companies for projects unrelated to this research. T.L. and V.F. are employees of 5 Prime Sciences. T.N. has received speaking fees from Boehringer Ingelheim and AstraZeneca regarding the projects unrelated to this research. The other authors declare no competing interests.
